Xelucip contains Relugolix is an oral medication classified as a gonadotropin-releasing hormone (GnRH) receptor antagonist. It is primarily used in the treatment of advanced prostate cancer in adult men. Relugolix functions by competitively binding to and blocking GnRH receptors in the anterior pituitary gland. This inhibition prevents GnRH from stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a decrease in testosterone production. Since certain prostate cancer cells rely on testosterone for growth, reducing its levels can slow or halt the progression of the disease. Relugolix is indicated for the treatment of adult men with advanced prostate cancer.

Xelucip offers a convenient oral treatment option for men with advanced prostate cancer, providing an alternative to injectable therapies. Its mechanism of action effectively reduces testosterone levels, thereby inhibiting cancer progression. As with any medication, it is essential to consider potential side effects and individual patient factors to ensure optimal outcomes. Regular monitoring and open communication with healthcare providers are crucial components of successful treatment with relugolix.

Dosage and Administration

The recommended dosing regimen for relugolix involves an initial loading dose followed by daily maintenance doses. Specifically, patients are advised to take a 360 mg loading dose on the first day, followed by 120 mg once daily thereafter. It is important to take the medication at the same time each day to maintain consistent blood levels.

Side Effects

Common side effects include:

• Hot flashes
• Increased blood sugar levels
• Fatigue
• Diarrhea
• Constipation
• Mild weight gain

Patients may also experience a decrease in bone mineral density over time, which could increase the risk of fractures. Regular monitoring and preventive measures are recommended to manage this risk.

Warnings and Precautions

• Cardiovascular Health: Relugolix may prolong the QT interval, potentially leading to heart rhythm problems. Patients with a history of cardiovascular issues should be closely monitored.

• Fertility Considerations: The medication can impair fertility in males of reproductive potential. Discuss fertility preservation options prior to initiating treatment.

• Drug Interactions: Relugolix can interact with other medications, including those that affect the enzyme CYP3A4. Inform your healthcare provider of all medications and supplements you are taking to avoid potential interactions.

Pharmacokinetics

After oral administration, relugolix is rapidly absorbed, reaching peak plasma concentrations approximately 2.5 hours post-dose. The drug is primarily metabolized in the liver and has a half-life of about 25 hours, allowing for once-daily dosing. It is excreted mainly through feces, with a smaller proportion eliminated via urine.